title: Cancer immunotherapy: exploiting neoepitopes.
abstract: The efficacy of cancer vaccines has long been hampered by insufficient definition of tumor-specific antigens. A recent study by Kreiter et al. published in Nature has provided a blueprint for a patient-tailored approach to develop individualized RNA vaccines.
authors.affiliation: 1] DKTK Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center, Heidelberg, Germany [2] Neurology Clinic, University Hospital Heidelberg and National Center for Tumor Diseases, Heidelberg, Germany.
authors.forename: Michael
authors.initials: M
authors.lastname: Platten
authors.affiliation: 1] Dept. Molecular Oncology of Gastrointestinal Tumors, German Cancer Research Center, Heidelberg, Germany [2] European Pancreas Center, Surgery Clinic, University Hospital Heidelberg, Heidelberg, Germany.
authors.forename: Rienk
authors.initials: R
authors.lastname: Offringa
mesh_terms: D000818:Animals; D018984:Epitopes, T-Lymphocyte / Q000235:genetics*; D005260:Female; D000949:Histocompatibility Antigens Class II / Q000235:genetics* / Q000276:immunology*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D008546:Melanoma, Experimental / Q000276:immunology* / Q000628:therapy*; D009154:Mutation / Q000235:genetics*
chemical_list: D018984:Epitopes, T-Lymphocyte; D000949:Histocompatibility Antigens Class II